Abstract LB 3 LB 3 Prophylactic antibiotics for the prevention of infection following operative vaginal delivery: the ANODE trial
OBJECTIVE:
To compare the incidence of confirmed or suspected maternal infection in the first six weeks after operative vaginal delivery amongst women who have been randomised to receive a prophylactic antibiotic versus those who received a placebo. STUDY DESIGN: In this multicentre, randomised, blinded, placebocontrolled trial, women who had undergone operative vaginal delivery at 36+0 weeks or greater gestation, with no indication for ongoing prescription of antibiotics in the postpartum period and no contra-indications to prophylactic co-amoxiclav, were randomised to receive a single intravenous dose of prophylactic co-amoxiclav or placebo. The primary outcome was confirmed or suspected maternal infection within 6 weeks of delivery, as defined by one of (a) a new prescription of antibiotics for presumed perineal wound-related infection, endometritis or uterine infection, urinary tract infection with systemic features or other systemic infection, (b) systemic infection confirmed with a culture or (c) endometritis as defined by the US Centers for Disease Control and Prevention. Assuming a 4% incidence of the primary outcome, a study with 90% power at the two-sided 5% level of significance with an estimated 5% loss to follow-up required 1,712 per group, total 3,424. RESULTS: 3,427 women were randomised; 3,420 were included in the primary intention to treat analysis, 1715 in the co-amoxiclav and 1705 in the placebo group. Primary outcome data were missing for 195 women (5.7%). Final results show that the overall primary outcome rate was higher than anticipated (486/3225 women, 15.1%). Women receiving co-amoxiclav had a significantly lower rate of confirmed or suspected infection (11.1%, n¼180/1619) than women in the placebo group (19.1%, n¼306/1606) (Risk ratio 0.58, 95% confidence interval 0.49-0.69, p<0.001). CONCLUSION: A single dose of prophylactic antibiotic following operative vaginal delivery is effective to prevent the primary outcome of confirmed or presumed maternal infection. In the context of growing concerns about antibiotic resistance, this trial provides robust evidence of efficacy for the use of routine prophylactic antibiotics at operative vaginal delivery. Late-Breaking Abstract ajog.org
